NO965564L - Medical application of bromelain - Google Patents

Medical application of bromelain

Info

Publication number
NO965564L
NO965564L NO965564A NO965564A NO965564L NO 965564 L NO965564 L NO 965564L NO 965564 A NO965564 A NO 965564A NO 965564 A NO965564 A NO 965564A NO 965564 L NO965564 L NO 965564L
Authority
NO
Norway
Prior art keywords
bromelain
medical application
modulator
pineapple
stalk
Prior art date
Application number
NO965564A
Other languages
Norwegian (no)
Other versions
NO965564D0 (en
Inventor
Tracey Lehanne Mynott
Christian Engwerda
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of NO965564D0 publication Critical patent/NO965564D0/en
Publication of NO965564L publication Critical patent/NO965564L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bromelain, en blanding av enzymer avledet fra stilken av ananas, er funnet å være en modulator av intra- cellulær signaltransduksjon, spesielt en modulator av reaksjonsveier hvori inositolfosfater spiller en rolle, og er derfor anvendelig ved behandling av forskjellige sykdommer og tilstander som formidles av disse intracellulære signalreaksjonsveier.Bromelain, a mixture of enzymes derived from the stalk of pineapple, has been found to be a modulator of intracellular signal transduction, especially a modulator of reaction pathways in which inositol phosphates play a role, and is therefore useful in the treatment of various diseases and conditions mediated by these. intracellular signaling pathways.

NO965564A 1994-06-24 1996-12-23 Medical application of bromelain NO965564L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412711A GB9412711D0 (en) 1994-06-24 1994-06-24 Medical use of bromelain
PCT/GB1995/001501 WO1996000082A1 (en) 1994-06-24 1995-06-26 Medical use of bromelain

Publications (2)

Publication Number Publication Date
NO965564D0 NO965564D0 (en) 1996-12-23
NO965564L true NO965564L (en) 1997-02-24

Family

ID=10757263

Family Applications (1)

Application Number Title Priority Date Filing Date
NO965564A NO965564L (en) 1994-06-24 1996-12-23 Medical application of bromelain

Country Status (13)

Country Link
EP (1) EP0766565A1 (en)
JP (1) JPH10502073A (en)
KR (1) KR970703784A (en)
CN (1) CN1151119A (en)
AU (1) AU2749395A (en)
CA (1) CA2193654A1 (en)
FI (1) FI965204A (en)
GB (1) GB9412711D0 (en)
IL (1) IL114331A0 (en)
NO (1) NO965564L (en)
TW (1) TW403654B (en)
WO (1) WO1996000082A1 (en)
ZA (1) ZA955292B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526691D0 (en) * 1995-12-29 1996-02-28 Cortecs Ltd Medical use of proteases
EP1012305A1 (en) * 1997-02-25 2000-06-28 Cortecs (UK) Limited Component of bromelain
WO1998038319A1 (en) * 1997-02-25 1998-09-03 Cortecs (Uk) Limited Component of bromelain
US20020102253A1 (en) * 1997-02-25 2002-08-01 Mynott Tracey Lehanne Component of bromelain
NO304766B1 (en) 1997-06-16 1999-02-08 Sintef fingerprint Sensor
DE19726255C2 (en) * 1997-06-20 2000-03-16 Mucos Pharma Gmbh & Co Influence of cytokines by proteolytic enzymes and rutoside
DE19726254C2 (en) * 1997-06-20 1999-10-21 Mucos Pharma Gmbh & Co Tolerance induction through proteases
DE19726244C2 (en) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Use of proteolytic enzymes and rutoside to prevent or treat graft rejection
GB9713667D0 (en) * 1997-06-27 1997-09-03 Cortecs Ltd Enhancement of intestinal permeability
GB9819137D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Component of bromelain
GB9819138D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Nucleic acids and proteins from pineapple stem
DE19847114A1 (en) * 1998-10-13 2000-04-20 Mucos Pharma Gmbh & Co Use of proteolytic enzymes to modulate hyperactive T cells, especially for symptomatic treatment of immune-mediated inflammatory diseases, e.g. multiple sclerosis, diabetes, arthritis or glomerulonephritis
WO2000035436A2 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
DE19957318A1 (en) * 1999-11-29 2001-06-21 Mucos Pharma Gmbh & Co Influence of TGF-beta by proteolytic enzymes
DE10018980A1 (en) * 2000-04-17 2001-11-08 Mucos Pharma Gmbh & Co Prophylaxis and therapy of diabetes mellitus I using proteolytic enzymes
EP1208849B1 (en) * 2000-11-28 2015-10-28 URSAPHARM Arzneimittel GmbH Use of bromelain for adjuvant therapy during wound healing process
TW201419131A (en) 2012-11-09 2014-05-16 Health & Life Co Ltd Voice-assisted biomedical sensing apparatus
US9526768B2 (en) * 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225122A (en) * 1983-05-23 1984-12-18 Kaken Pharmaceut Co Ltd Remedy and improver for cancerous cachexia
EP0421023B1 (en) * 1989-10-06 1995-03-15 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Catabolic enzymes for the induction of the tumour necrosis factor (TNF)
DE4302060A1 (en) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Use of bromelain as CD44 surface molecule modifier
GB9313188D0 (en) * 1993-06-25 1993-08-11 Cortecs Ltd Medical use of enzymes

Also Published As

Publication number Publication date
KR970703784A (en) 1997-08-09
NO965564D0 (en) 1996-12-23
CN1151119A (en) 1997-06-04
FI965204A (en) 1997-02-21
TW403654B (en) 2000-09-01
EP0766565A1 (en) 1997-04-09
WO1996000082A1 (en) 1996-01-04
JPH10502073A (en) 1998-02-24
AU2749395A (en) 1996-01-19
FI965204A0 (en) 1996-12-23
CA2193654A1 (en) 1996-01-04
IL114331A0 (en) 1995-10-31
ZA955292B (en) 1997-07-28
GB9412711D0 (en) 1994-08-17

Similar Documents

Publication Publication Date Title
NO965564L (en) Medical application of bromelain
AU2611997A (en) Medical Treatment
MX9606404A (en) Pharmaceutical compositions and methods for modulating signal transduction.
AU635961B2 (en) Novel peptidase and isomerase inhibitors
AU3717395A (en) Compositions for the treatment of skin disorders
AU1373499A (en) Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease
HK1015139A1 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
NO944997D0 (en) Thrombin blood fraction for use in a medical procedure
AU4304196A (en) Novel sulfonamides
GB9514451D0 (en) Sustained-release formulation
CA2264750A1 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
AU2002234806A1 (en) Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders
HUP0001014A2 (en) Use of gastrointestinal lipase inhibitors
DE69432413D1 (en) TREATMENT OF DEGENERATIVE VESSEL DISEASES BY MODULATING THE ENDOGENIC NITROGEN PRODUCTION OR ACTIVITY
WO1996040113A3 (en) Phosphatase inhibitors
NO955258L (en) Medical use of enzymes
WO1997024138A3 (en) Medical use of proteases
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
AU6303798A (en) Component of bromelain
MX9700209A (en) Medical use of bromelain.
WO1999050671A3 (en) Toso as a target for drug screening
HUP0004647A2 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
WO2002061065A3 (en) Phosphorylated glyoxalase i and its use